🚨 #ESMO26 | SAFFRON Phase III | NEJM

Osimertinib + savolitinib vs chemotherapy in MET-positive EGFRm NSCLC after osimertinib:

✅ PFS: 7.6 vs 5.4 mo (HR 0.55)
✅ OS: 17.8 vs 12.9 mo (HR 0.68)
✅ ORR: 51% vs 27%

🎯 A potential new standard of care!

#LungCancer #NSCLC